Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Seifert

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapyPeter Dubsky, Paul Sevelda, Raimund Jakesz, et al.
Journal of Human Genetics|August 14, 2020
The clinical-phenotype continuum in DYNC1H1-related disorders-genomic profiling and proposal for a novel classificationLena-Luise Becker, Hormos Salimi Dafsari, Jens Schallner, et al.
The Lancet. Oncology|June 7, 2011
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trialMichael Gnant, Brigitte Mlineritsch, Herbert Stoeger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast CancerChristian F Singer, Yen Y Tan, Florian Fitzal, et al.
Cell Reports|December 26, 2019
Mutual Zonated Interactions of Wnt and Hh Signaling Are Orchestrating the Metabolism of the Adult Liver in Mice and HumanErik Kolbe, Susanne Aleithe, Christiane Rennert, et al.
The Lancet. Oncology|August 23, 2008
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudyMichael Gnant, Brigitte Mlineritsch, Gero Luschin-Ebengreuth, et al.
The New England Journal of Medicine|February 14, 2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancerMichael Gnant, Brigitte Mlineritsch, Walter Schippinger, et al.
Cancers|January 1, 2020
Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor OriginJulia Biedermann, Matthias Preussler, Marina Conde, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 15, 2023
Validation of a prediction system for risk of kidney allograft failure in pediatric kidney transplant recipients: An international observational studyJulien Hogan, Gillian Divard, Olivier Aubert, et al.
Frontiers in Surgery|March 2, 2023
SEVTAR-A multicenter randomized controlled trial to investigate the impact of prophylactic endoluminal placed vacuum sponge for prevention of anastomotic leakage after low rectal resectionsLeif Schiffmann, Matthias Becker, Leendert Develing, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapyPeter Dubsky, Paul Sevelda, Raimund Jakesz, et al.
Journal of Human Genetics|August 14, 2020
The clinical-phenotype continuum in DYNC1H1-related disorders-genomic profiling and proposal for a novel classificationLena-Luise Becker, Hormos Salimi Dafsari, Jens Schallner, et al.
The Lancet. Oncology|June 7, 2011
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trialMichael Gnant, Brigitte Mlineritsch, Herbert Stoeger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast CancerChristian F Singer, Yen Y Tan, Florian Fitzal, et al.
Cell Reports|December 26, 2019
Mutual Zonated Interactions of Wnt and Hh Signaling Are Orchestrating the Metabolism of the Adult Liver in Mice and HumanErik Kolbe, Susanne Aleithe, Christiane Rennert, et al.
The Lancet. Oncology|August 23, 2008
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudyMichael Gnant, Brigitte Mlineritsch, Gero Luschin-Ebengreuth, et al.
The New England Journal of Medicine|February 14, 2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancerMichael Gnant, Brigitte Mlineritsch, Walter Schippinger, et al.
Cancers|January 1, 2020
Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor OriginJulia Biedermann, Matthias Preussler, Marina Conde, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 15, 2023
Validation of a prediction system for risk of kidney allograft failure in pediatric kidney transplant recipients: An international observational studyJulien Hogan, Gillian Divard, Olivier Aubert, et al.
Frontiers in Surgery|March 2, 2023
SEVTAR-A multicenter randomized controlled trial to investigate the impact of prophylactic endoluminal placed vacuum sponge for prevention of anastomotic leakage after low rectal resectionsLeif Schiffmann, Matthias Becker, Leendert Develing, et al.
Pageof 10